{
    "clinical_study": {
        "@rank": "82450", 
        "arm_group": [
            {
                "arm_group_label": "TRV130 1 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 1 mg IV Q4H x 48 h"
            }, 
            {
                "arm_group_label": "TRV130 2 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 2 mg IV Q4H x 48 h"
            }, 
            {
                "arm_group_label": "TRV130 3 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 3 mg IV Q4H x 48 h"
            }, 
            {
                "arm_group_label": "TRV130 4 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 4 mg IV Q4H x 48 h"
            }, 
            {
                "arm_group_label": "Morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "Morphine 4 mg IV Q4H x 48 h"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (D5W) IV Q4H x 48 h"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with\n      placebo in patients with acute postoperative pain after bunionectomy."
        }, 
        "brief_title": "A Study of TRV130 for the Treatment of Pain After Bunionectomy", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Pain", 
        "detailed_description": {
            "textblock": "The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with\n      placebo in patients with acute postoperative pain after bunionectomy.  Additional objectives\n      are to evaluate the efficacy and safety of TRV130 compared to morphine.  Pharmacokinetics of\n      TRV130 and morphine will be evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and\n             internal fixation) with no additional collateral procedures.\n\n          -  Experiences a pain intensity rating of \u2265 4 on an 11 point NRS\n\n          -  Able to provide written informed consent before any study procedure.\n\n        Exclusion Criteria:\n\n          -  ASA Physical Status Classification System classification of P3 or worse\n\n          -  Has surgical or post-surgical complications.\n\n          -  Has clinically significant medical conditions or history of such conditions that may\n             interfere with the interpretation of efficacy, safety, or tolerability data obtained\n             in the trial, or may interfere with the absorption, distribution, metabolism, or\n             excretion of drugs.\n\n          -  Has previously participated in another TRV130 clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100748", 
            "org_study_id": "CP130-2001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TRV130 1 mg", 
                    "TRV130 2 mg", 
                    "TRV130 3 mg", 
                    "TRV130 4 mg"
                ], 
                "description": "TRV130 1 - 4 mg will be administered every 4 hours", 
                "intervention_name": "TRV130", 
                "intervention_type": "Drug", 
                "other_name": "TRV130"
            }, 
            {
                "arm_group_label": "Morphine", 
                "description": "Morphine 4 mg will be administered every 4 hours", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug", 
                "other_name": "Morphine sulphate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered every 4 hours", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dextrose 5% in water", 
                    "D5W"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "moderate to severe acute pain", 
            "bunionectomy"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Recruitment Department", 
                    "phone": "866-788-3921"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85027"
                    }, 
                    "name": "Premier Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Recruitment Department", 
                    "phone": "800-320-1630"
                }, 
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Premier Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Recruitment Department", 
                    "phone": "210-225-5437"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78209"
                    }, 
                    "name": "ICON Development Solutions"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy", 
        "overall_contact": {
            "email": "rsubach@trevenainc.com", 
            "last_name": "Ruth A Subach, PharmD", 
            "phone": "610-354-8840", 
            "phone_ext": "250"
        }, 
        "overall_official": {
            "affiliation": "Trevena Inc.", 
            "last_name": "Franck Skobieranda, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pain intensity will be evaluated by an 11-point numeric rating scale administered intermittently over 48 hours", 
            "measure": "Reduction of Pain Intensity following Bunionectomy", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Trevena Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trevena Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}